Developer docs
API playgroundTry for free, no card

Search company profiles

ImCheck Therapeutics

Full company profile

uuid0000kfh

Namestring
ImCheck Therapeutics
Legal namestring
ImCheck Therapeutics
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarseille, France
HQ citystring
Marseille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
immunotherapeutic antibodies, gamma delta T cells, cancer immunotherapy, butyrophilin targeting, monoclonal antibody therapeutics
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy Biopharmaceuticals
Social media profiles2 records
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ImCheck Therapeutics designs and develops first-in-class immunotherapeutic monoclonal antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules to selectively activate γ9δ2 T cells. Its lead candidate ICT01 is a humanized anti-BTN3A antibody for immuno-oncology indications including acute myeloid leukemia and solid tumors, while ICT41 extends the same γ9δ2 activation mechanism to infectious diseases. The company is clinical-stage and pre-revenue, focused on advancing its pipeline through regulatory and clinical milestones.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 96% composite complete remission (CRc) rate and 74% complete remission (CR) in newly diagnosed AML patients treated with ICT01 + azacitidine + venetoclax
+4 more records
Product overview1 text field

ImCheck Therapeutics is developing a pipeline of novel immunotherapeutic antibodies targeting butyrophilins (BTN) and BTN-like (BTNL) molecules. The core products are ICT01 and ICT41, both anti-BTN3A monoclonal antibodies that selectively activate γ9δ2 T cells. ICT01 focuses on immuno-oncology applications for solid tumors and hematologic malignancies, while ICT41 targets infectious diseases. The company is leveraging its proprietary understanding of butyrophilin biology to create a diversified pipeline with first-in-class therapeutic potential.

Product and service2 records
1ICT01
CategoryCancer Immunotherapy
Description

ICT01 is a humanized, anti-BTN3A (CD277) monoclonal antibody that selectively activates γ9δ2 T cells for immuno-oncology applications. It promotes tumor cell recognition and elimination by activating the anti-tumor immune response, leading to γ9δ2 T-cell migration from circulation into tumor tissue and secretion of pro-inflammatory cytokines (IFNγ, TNFα). ICT01 is being developed for acute myeloid leukemia (AML), solid tumors (melanoma, urothelial cell carcinoma, head and neck squamous cell carcinoma, ovarian cancer), and hematologic malignancies, including patients ineligible for intensive chemotherapy and TP53-mutated AML. ICT01 has received FDA Fast Track Designation (September 2024) and Orphan Drug Designation from both the FDA and EMA (July 2025).

2ICT41
CategoryInfectious Disease Immunotherapy
Description

ICT41 is a humanized, anti-BTN3A monoclonal antibody that selectively activates γ9Vδ2 T cells for the treatment of infectious diseases. Once activated, these cells orchestrate a broad immune response through multiple pathways involving granulocytes, CD8 T cells, and NK cells capable of combatting viral, bacterial/mycobacterial, and parasitic infections. ICT41 is currently in proof-of-concept preclinical studies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Innate Pharma
TypeDirect peer
Description

French immuno-oncology company also headquartered in Marseille, developing antibody-based therapeutics leveraging innate immune cells including γδ T cells. Most directly comparable peer given overlapping geography, modality, and γδ T-cell biology focus.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered T-cell receptor (TCR) therapies for solid tumors, with overlapping focus on T-cell receptor biology and cancer immunotherapy, though using cell therapy rather than antibody modality.

TypeDirect peer
Description

Clinical-stage biotech developing monoclonal antibody therapeutics for cancer, including bispecifics and antibody-drug conjugates. Comparable as a fellow antibody-focused oncology biotech with multiple clinical-stage programs.

TypeDirect peer
Description

Clinical-stage oncology biotech developing antibody-based therapeutics (Probody platform) for cancer, with similar modality, clinical-stage profile, and combination therapy focus in immuno-oncology.

TypeBroad incumbent
Description

Established antibody-focused biotech with broad oncology pipeline including approved bispecifics (Epkinly). Comparable antibody platform approach but broader, more mature, and commercial-stage versus ImCheck's clinical-stage focus.

TypeEmerging player
Description

Commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer. Comparable as a T-cell focused oncology player, though ImCheck's γδ T-cell approach is mechanistically distinct.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing antibody-based therapeutics with focus on novel immune targets. Comparable as a fellow clinical-stage biotech pursuing innovative immuno-oncology mechanisms.

8Pieris Pharmaceuticals
TypeEmerging player
Description

Clinical-stage biotech developing proprietary anticalin-based protein therapeutics for cancer and respiratory disease. Comparable as a smaller clinical-stage biotech with proprietary protein-engineering platform.

TypeBroad incumbent
Description

Global pharmaceutical leader with deep oncology franchise including checkpoint inhibitor Imfinzi and ADC Enhertu. Comparable as a major oncology player whose checkpoint inhibitor and ADC franchises compete in ImCheck's combination therapy landscape.

TypeBroad incumbent
Description

French-headquartered global pharmaceutical company with significant oncology presence including hematology assets. Comparable as a French-headquartered major pharma player active in ImCheck's target indications and geographic ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImCheck Therapeutics

Cancer Immunotherapy Biopharmaceuticalsimchecktherapeutics.com

ImCheck Therapeutics firmographics

Firmographics
Name
ImCheck Therapeutics
Legal name
ImCheck Therapeutics
Website
https://imchecktherapeutics.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

ImCheck Therapeutics industry classification

Industry
Product category
Cancer Immunotherapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Immunotherapeutic antibodies
  • Gamma delta T cells
  • Cancer immunotherapy
  • Butyrophilin targeting
  • Monoclonal antibody therapeutics

Where ImCheck Therapeutics is headquartered

Location

Headquarters

HQ city
Marseille
HQ country
France
HQ region
Europe

Markets served

ImCheck Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels3 records

ImCheck Therapeutics product offering

Product offering

Core offering

ImCheck Therapeutics designs and develops first-in-class immunotherapeutic monoclonal antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules to selectively activate γ9δ2 T cells. Its lead candidate ICT01 is a humanized anti-BTN3A antibody for immuno-oncology indications including acute myeloid leukemia and solid tumors, while ICT41 extends the same γ9δ2 activation mechanism to infectious diseases. The company is clinical-stage and pre-revenue, focused on advancing its pipeline through regulatory and clinical milestones.

Product overview

ImCheck Therapeutics is developing a pipeline of novel immunotherapeutic antibodies targeting butyrophilins (BTN) and BTN-like (BTNL) molecules. The core products are ICT01 and ICT41, both anti-BTN3A monoclonal antibodies that selectively activate γ9δ2 T cells. ICT01 focuses on immuno-oncology applications for solid tumors and hematologic malignancies, while ICT41 targets infectious diseases. The company is leveraging its proprietary understanding of butyrophilin biology to create a diversified pipeline with first-in-class therapeutic potential.

Differentiator

Problem solved

Functional benefit

Products and services

  • ICT01 ICT01 is a humanized, anti-BTN3A (CD277) monoclonal antibody that selectively activates γ9δ2 T cells for immuno-oncology applications. It promotes tumor cell recognition and elimination by activating the anti-tumor immune response, leading to γ9δ2 T-cell migration from circulation into tumor tissue and secretion of pro-inflammatory cytokines (IFNγ, TNFα). ICT01 is being developed for acute myeloid leukemia (AML), solid tumors (melanoma, urothelial cell carcinoma, head and neck squamous cell carcinoma, ovarian cancer), and hematologic malignancies, including patients ineligible for intensive chemotherapy and TP53-mutated AML. ICT01 has received FDA Fast Track Designation (September 2024) and Orphan Drug Designation from both the FDA and EMA (July 2025).
  • ICT41 ICT41 is a humanized, anti-BTN3A monoclonal antibody that selectively activates γ9Vδ2 T cells for the treatment of infectious diseases. Once activated, these cells orchestrate a broad immune response through multiple pathways involving granulocytes, CD8 T cells, and NK cells capable of combatting viral, bacterial/mycobacterial, and parasitic infections. ICT41 is currently in proof-of-concept preclinical studies.

Quantifiable outcome

  • 96% composite complete remission (CRc) rate and 74% complete remission (CR) in newly diagnosed AML patients treated with ICT01 + azacitidine + venetoclax
  • +4 more outcomes

Companies that use ImCheck Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

ImCheck Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ImCheck Therapeutics partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights5 records

ImCheck Therapeutics competitors and assessment

Company assessment

Direct peers

  • Innate Pharma: French immuno-oncology company also headquartered in Marseille, developing antibody-based therapeutics leveraging innate immune cells including γδ T cells. Most directly comparable peer given overlapping geography, modality, and γδ T-cell biology focus.
  • Adaptimmune: Clinical-stage cell therapy company developing engineered T-cell receptor (TCR) therapies for solid tumors, with overlapping focus on T-cell receptor biology and cancer immunotherapy, though using cell therapy rather than antibody modality.
  • MacroGenics: Clinical-stage biotech developing monoclonal antibody therapeutics for cancer, including bispecifics and antibody-drug conjugates. Comparable as a fellow antibody-focused oncology biotech with multiple clinical-stage programs.
  • CytomX Therapeutics: Clinical-stage oncology biotech developing antibody-based therapeutics (Probody platform) for cancer, with similar modality, clinical-stage profile, and combination therapy focus in immuno-oncology.

Broad incumbents

  • Genmab: Established antibody-focused biotech with broad oncology pipeline including approved bispecifics (Epkinly). Comparable antibody platform approach but broader, more mature, and commercial-stage versus ImCheck's clinical-stage focus.
  • AstraZeneca: Global pharmaceutical leader with deep oncology franchise including checkpoint inhibitor Imfinzi and ADC Enhertu. Comparable as a major oncology player whose checkpoint inhibitor and ADC franchises compete in ImCheck's combination therapy landscape.
  • Servier: French-headquartered global pharmaceutical company with significant oncology presence including hematology assets. Comparable as a French-headquartered major pharma player active in ImCheck's target indications and geographic ecosystem.

Emerging players

  • Iovance Biotherapeutics: Commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer. Comparable as a T-cell focused oncology player, though ImCheck's γδ T-cell approach is mechanistically distinct.
  • Compugen: Clinical-stage immuno-oncology company developing antibody-based therapeutics with focus on novel immune targets. Comparable as a fellow clinical-stage biotech pursuing innovative immuno-oncology mechanisms.
  • Pieris Pharmaceuticals: Clinical-stage biotech developing proprietary anticalin-based protein therapeutics for cancer and respiratory disease. Comparable as a smaller clinical-stage biotech with proprietary protein-engineering platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

ImCheck Therapeutics social profiles

Digital presence

ImCheck Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImCheck Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

ImCheck Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImCheck Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImCheck Therapeutics

What does ImCheck Therapeutics do?

ImCheck Therapeutics designs and develops first-in-class immunotherapeutic monoclonal antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules to selectively activate γ9δ2 T cells. Its lead candidate ICT01 is a humanized anti-BTN3A antibody for immuno-oncology indications including acute myeloid leukemia and solid tumors, while ICT41 extends the same γ9δ2 activation mechanism to infectious diseases. The company is clinical-stage and pre-revenue, focused on advancing its pipeline through regulatory and clinical milestones.

Is ImCheck Therapeutics a public or private company?

ImCheck Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was ImCheck Therapeutics founded?

ImCheck Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is ImCheck Therapeutics based?

ImCheck Therapeutics is headquartered in Marseille, France, in the Europe region.

Who are ImCheck Therapeutics's main competitors?

Direct peers on record are Innate Pharma, Adaptimmune, MacroGenics and CytomX Therapeutics. Broad incumbents are Genmab, AstraZeneca and Servier. Emerging players are Iovance Biotherapeutics, Compugen and Pieris Pharmaceuticals.

Does ImCheck Therapeutics have an API?

No public API is recorded for ImCheck Therapeutics.

What industry is ImCheck Therapeutics in?

ImCheck Therapeutics's product category is Cancer Immunotherapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.European BiotechnologyEurope’s imperative: Early-stage investors and company creationEuropean biotech now has large venture funds capable of scaling mature companies, with notable exits like Amolyt Pharma (acquired by AstraZeneca) and Imcheck Therapeutics (acquired by Ipsen) for potential values exceeding €1 billion each. However, the ecosystem remains constrained by limited early-stage financing for company creation and bridging academic discoveries to scalable businesses. The article argues that sovereign funds and industry investors must strengthen early-stage investments across Europe to sustain the biotech ecosystem and prevent entrepreneurs from seeking funding elsewhere.FailoryTop 51 Marseille Startups to Watch in 2026The article presents a list of the top 51 startups in Marseille to watch in 2026, highlighting the city's growing ecosystem in life sciences, SaaS, and sustainable manufacturing. It specifically mentions ImCheck Therapeutics as a major player that has raised €193.1M for antibody development. The content also includes promotional material for various startup resources such as investor lists and funding tools.BioSpaceIpsen completes acquisition of ImCheck Therapeutics, expanding oncology pipelineIpsen announced on 15 December 2025 that it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company specializing in next-generation immuno-oncology therapies. The transaction expands Ipsen's oncology pipeline and strengthens its position in the immunotherapy space. ImCheck Therapeutics now becomes part of Ipsen's portfolio of transformative medicines in oncology, rare disease, and neuroscience.GlobeNewswireIpsen completes acquisition of ImCheck Therapeutics, expanding oncology pipelineIpsen completed the acquisition of ImCheck Therapeutics, a French biotechnology company developing next-generation immuno-oncology therapies. The deal expands Ipsen's oncology pipeline, with ImCheck's assets integrated into Ipsen's broader oncology, rare disease, and neuroscience portfolio.IpsenIpsen completes acquisition of ImCheck Therapeutics, expanding oncology pipelineIpsen announced on December 15, 2025, that it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company specializing in next-generation immuno-oncology therapies. The deal expands Ipsen's oncology pipeline, strengthening the global biopharmaceutical company's capabilities in cancer treatment development. This acquisition aligns with Ipsen's strategy of fueling pipeline growth through external innovation across its three therapeutic areas.MarketScreenerIpsen completes acquisition of ImCheck TherapeuticsIpsen has completed its acquisition of ImCheck Therapeutics, enhancing its portfolio in the pharmaceuticals sector. This acquisition aligns with Ipsen's strategy to expand its capabilities in the biotech industry. The move reflects a growing trend of consolidation within the pharmaceutical market.GlobeNewswireIpsen completes acquisition of ImCheck Therapeutics, expanding oncology pipelineIpsen has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company focused on next-generation immuno-oncology therapies. The deal expands Ipsen's oncology pipeline, strengthening its position in the immuno-oncology space. This acquisition, announced on December 15, 2025, represents a strategic expansion for the global biopharmaceutical company.GlobeNewswireImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025ImCheck Therapeutics announced updated Phase I/II EVICTION trial results for ICT01, a first-in-class γ9δ2 T-cell activator, showing that over 90% of newly diagnosed AML patients ineligible for intensive chemotherapy achieved complete remission when treated with the 10mg dose in combination with azacitidine and venetoclax. The 12-month overall survival rate reached 62% compared to approximately 54% for the standard Aza-Ven regimen, with the FDA endorsing the 10mg dose for late-stage development, and ICT01 receiving Orphan Drug Designation from both FDA and EMA. The results arrive as ImCheck proceeds toward closing its acquisition by Ipsen, anticipated by the end of Q1 2026.GlobeNewswireImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual MeetingImCheck Therapeutics announced an oral presentation at ASH 2025 on ICT01 data from the EVICTION study, a Phase I/II trial in AML. The presentation highlights high remission and overall survival rates in older or unfit patients. The company also noted Ipsen's planned acquisition of ImCheck, closing by Q1 2026.